Evidence map›Paper›PMID 37315930›Full record

ArticleThe clinical respiratory journal2023

Rapid vision improvement by using icotinib in a patient with bilateral choroidal metastases symmetrically from lung cancer.

Chaoran Li, Xue E Wang, Lei Yan, Yani Zhao, Yun Kui Zhu

Open access · goldAbstract readCase Reports
In one paragraph

Article in The clinical respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chaoran LiDepartment of Respiratory and Critical Care Medicine, Xi'an International Medical Center Hospital, Xian, China.
Xue E WangDepartment of Respiratory and Critical Care Medicine, Xi'an International Medical Center Hospital, Xian, China.
Lei YanDepartment of Respiratory and Critical Care Medicine, Xi'an International Medical Center Hospital, Xian, China.
Yani ZhaoDepartment of Respiratory and Critical Care Medicine, Xi'an International Medical Center Hospital, Xian, China.
Yun Kui ZhuDepartment of Respiratory and Critical Care Medicine, Xi'an International Medical Center Hospital, Xian, China.ORCID https://orcid.org/0000-0003-4753-7940
Medical Center Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe metastases of lung cancer to bilateral choroids symmetrically and simultaneously are very rare. Almost all patients with choroid metastasis can be treated with external beam radiotherapy in order to increase quality of life and preserve vision. MATERIAL AND

methodsWe documented a case and studied the effect of icotinib on choroidal metastases in bilateral eyes simultaneously from pulmonary adenocarcinoma.

resultsA 49-year-old Chinese man presented with bilateral vision losing simultaneously for 4 weeks, it was as an initial presentation in the clinical. The examinations with ophthalmofundoscopy, ultrasonography, and fluorescein angiography showed the lesions in bilateral choroids, two solitary juxtapapillary yellow-white choroidal metastases inferior to the optic discs with bleeding. Positron emission tomography confirmed the choroidal metastases and further proved that it was from lung cancer with lymph nodes and multiple bone metastasis. The biopsy taken from the lung by bronchoscopy and needle biopsy from supraclavicular lymph nodes revealed the pulmonary adenocarcinoma with epithelial growth factor receptor mutation (exon 21). The patient was treated with oral icotinib (125 mg, three times a day, TID). Five days after starting icotinib therapy, the patient's visions were rapidly recovered. Two months after the treatment with icotinib, the choroidal metastases regressed to small lesions, and the visions were preserved to before. The lung tumor and other metastatic lesions were partly regressive. There was no evidence of recurrence for eye lesions at 15-months follow-up. After 17 months treating by icotinib, the patient presented headache and dizzy with multiple brain metastases determined by magnetic resonance imaging; however, the lesions of the choroidal metastases remained progressing-free. Almonertinib with radiotherapy were used to treat the brain metastases, and he is surviving with progress-free more than 2 years until now.

conclusionBilateral choroidal metastases from lung cancer symmetrically are very rare. Icotinib following by almonertinib was an alternative therapy for choroidal metastasis from non-small cell lung cancer with epithelial growth factor receptor mutation.

Indexed as

Adenocarcinoma of LungBrain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsAcrylamidesChoroidCrown EthersHumansIndolesMaleMiddle AgedPyrimidinesQuality of LifeQuinazolinesAcrylamidesaumolertinibCrown EthersicotinibIndolesPyrimidinesQuinazolinesalmonertinibbilateral choroidal metastasesicotinibnon-small-cell lung cancerpositron emission tomographyradiotherapy

Identifiers

PMID37315930
PMCPMC10363825
OpenAlexW4380686772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.